SHANGHAI, May 3, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation ("ShangPharma", NYSE: SHP) today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2010 with the United States Securities and Exchange Commission (the "SEC"). The annual report can be accessed on ShangPharma's website at http://www.ir.shangpharma.com under the Investor Relations section. ShangPharma will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of charge to its shareholders and ADS holders upon request. Requests should be directed to Lan Xie, VP of Finance and Operations, by email at IR@shangpharma.com.

About ShangPharma Corporation

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com. 


    For further information, contact:

    ShangPharma Corporation

    Lan Xie, VP of Finance and Operations
    E-mail: IR@shangpharma.com

    Christensen

    In New York
    Kimberly Minarovich
    Phone: +1 917-533-3268
    E-mail: kminarovich@christensenir.com

    In Hong Kong
    Tip Fleming
    Phone: +852-9212-0684
    Email: tfleming@ChristensenIR.com

SOURCE ShangPharma Corporation